Oral Hypoglycemic Agents and Insulin Analogues Market Report

Global and Region Oral Hypoglycemic Agents and Insulin Analogues Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Jul 29, 2022
  • PAGES：222
  • REPORT CODE：GMM884480
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of Oral Hypoglycemic Agents and Insulin Analogues market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Oral Hypoglycemic Agents and Insulin Analoguesmarket, defines the market attractiveness level of Oral Hypoglycemic Agents and Insulin Analogues market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Oral Hypoglycemic Agents and Insulin Analogues industry, describes the types of Oral Hypoglycemic Agents and Insulin Analogues market, the applications of major players and the market size, and deeply analyzes the current situation of the global Oral Hypoglycemic Agents and Insulin Analogues market and the development prospects and opportunities of Oral Hypoglycemic Agents and Insulin Analogues industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Oral Hypoglycemic Agents and Insulin Analogues market in Chapter 13.

    By Player:

    • Jiangsu Wanbang

    • Novo Nordisk

    • Tonghua Dongbao

    • Eli Lilly

    • United Laboratory

    • Ganlee

    • Biocon

    • Sanofi-Aventis

    By Type:

    • Insulin Secretagogues

    • Alpha-glucosidase Inhibitors

    • Insulin Sensitizers

    By End-User:

    • Hospitals

    • Drug Store

    • Others

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Oral Hypoglycemic Agents and Insulin Analogues Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Oral Hypoglycemic Agents and Insulin Analogues Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Oral Hypoglycemic Agents and Insulin Analogues Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Oral Hypoglycemic Agents and Insulin Analogues Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Oral Hypoglycemic Agents and Insulin Analogues Market Analysis and Outlook to 2022

    • 7.1 Global Oral Hypoglycemic Agents and Insulin Analogues Consumption (2017-2022)

    • 7.2 United States Oral Hypoglycemic Agents and Insulin Analogues Consumption (2017-2022)

    • 7.3 Europe Oral Hypoglycemic Agents and Insulin Analogues Consumption (2017-2022)

    • 7.4 China Oral Hypoglycemic Agents and Insulin Analogues Consumption (2017-2022)

    • 7.5 Japan Oral Hypoglycemic Agents and Insulin Analogues Consumption (2017-2022)

    • 7.6 India Oral Hypoglycemic Agents and Insulin Analogues Consumption (2017-2022)

    • 7.7 South Korea Oral Hypoglycemic Agents and Insulin Analogues Consumption (2017-2022)

    8 Region and Country-wise Oral Hypoglycemic Agents and Insulin Analogues Market Analysis and Outlook to 2028

    • 8.1 Global Oral Hypoglycemic Agents and Insulin Analogues Consumption Forecast (2022-2028)

    • 8.2 United States Oral Hypoglycemic Agents and Insulin Analogues Consumption Forecast (2022-2028)

    • 8.3 Europe Oral Hypoglycemic Agents and Insulin Analogues Consumption Forecast (2022-2028)

    • 8.4 China Oral Hypoglycemic Agents and Insulin Analogues Consumption Forecast (2022-2028)

    • 8.5 Japan Oral Hypoglycemic Agents and Insulin Analogues Consumption Forecast (2022-2028)

    • 8.6 India Oral Hypoglycemic Agents and Insulin Analogues Consumption Forecast (2022-2028)

    • 8.7 South Korea Oral Hypoglycemic Agents and Insulin Analogues Consumption Forecast (2022-2028)

    9 Global Oral Hypoglycemic Agents and Insulin Analogues Market Outlook by Types and Applications to 2022

    • 9.1 Global Oral Hypoglycemic Agents and Insulin Analogues Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Insulin Secretagogues Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Alpha-glucosidase Inhibitors Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Insulin Sensitizers Consumption and Growth Rate (2017-2022)

    • 9.2 Global Oral Hypoglycemic Agents and Insulin Analogues Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Drug Store Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Others Consumption and Growth Rate (2017-2022)

    10 Global Oral Hypoglycemic Agents and Insulin Analogues Market Outlook by Types and Applications to 2028

    • 10.1 Global Oral Hypoglycemic Agents and Insulin Analogues Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Insulin Secretagogues Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Alpha-glucosidase Inhibitors Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Insulin Sensitizers Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Oral Hypoglycemic Agents and Insulin Analogues Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Drug Store Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)

    11 Global Oral Hypoglycemic Agents and Insulin Analogues Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Oral Hypoglycemic Agents and Insulin Analogues Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Oral Hypoglycemic Agents and Insulin Analogues Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Oral Hypoglycemic Agents and Insulin Analogues Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Oral Hypoglycemic Agents and Insulin Analogues Market Competitive Analysis

    • 14.1 Jiangsu Wanbang

      • 14.1.1 Jiangsu Wanbang Company Details

      • 14.1.2 Jiangsu Wanbang Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Jiangsu Wanbang Oral Hypoglycemic Agents and Insulin Analogues Product and Service

    • 14.2 Novo Nordisk

      • 14.2.1 Novo Nordisk Company Details

      • 14.2.2 Novo Nordisk Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Novo Nordisk Oral Hypoglycemic Agents and Insulin Analogues Product and Service

    • 14.3 Tonghua Dongbao

      • 14.3.1 Tonghua Dongbao Company Details

      • 14.3.2 Tonghua Dongbao Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Tonghua Dongbao Oral Hypoglycemic Agents and Insulin Analogues Product and Service

    • 14.4 Eli Lilly

      • 14.4.1 Eli Lilly Company Details

      • 14.4.2 Eli Lilly Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Eli Lilly Oral Hypoglycemic Agents and Insulin Analogues Product and Service

    • 14.5 United Laboratory

      • 14.5.1 United Laboratory Company Details

      • 14.5.2 United Laboratory Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 United Laboratory Oral Hypoglycemic Agents and Insulin Analogues Product and Service

    • 14.6 Ganlee

      • 14.6.1 Ganlee Company Details

      • 14.6.2 Ganlee Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Ganlee Oral Hypoglycemic Agents and Insulin Analogues Product and Service

    • 14.7 Biocon

      • 14.7.1 Biocon Company Details

      • 14.7.2 Biocon Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Biocon Oral Hypoglycemic Agents and Insulin Analogues Product and Service

    • 14.8 Sanofi-Aventis

      • 14.8.1 Sanofi-Aventis Company Details

      • 14.8.2 Sanofi-Aventis Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Sanofi-Aventis Oral Hypoglycemic Agents and Insulin Analogues Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Oral Hypoglycemic Agents and Insulin Analogues

    • Figure Oral Hypoglycemic Agents and Insulin Analogues Picture

    • Table Global Oral Hypoglycemic Agents and Insulin Analogues Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Oral Hypoglycemic Agents and Insulin Analogues Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Oral Hypoglycemic Agents and Insulin Analogues Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Oral Hypoglycemic Agents and Insulin Analogues Consumption by Country (2017-2022)

    • Figure United States Oral Hypoglycemic Agents and Insulin Analogues Consumption and Growth Rate (2017-2022)

    • Table Europe Oral Hypoglycemic Agents and Insulin Analogues Consumption and Growth Rate (2017-2022)

    • Figure China Oral Hypoglycemic Agents and Insulin Analogues Consumption and Growth Rate (2017-2022)

    • Figure Japan Oral Hypoglycemic Agents and Insulin Analogues Consumption and Growth Rate (2017-2022)

    • Figure India Oral Hypoglycemic Agents and Insulin Analogues Consumption and Growth Rate (2017-2022)

    • Figure South Korea Oral Hypoglycemic Agents and Insulin Analogues Consumption and Growth Rate (2017-2022)

    • Figure Global Oral Hypoglycemic Agents and Insulin Analogues Consumption Forecast by Country (2022-2028)

    • Figure United States Oral Hypoglycemic Agents and Insulin Analogues Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Oral Hypoglycemic Agents and Insulin Analogues Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Oral Hypoglycemic Agents and Insulin Analogues Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Oral Hypoglycemic Agents and Insulin Analogues Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Oral Hypoglycemic Agents and Insulin Analogues Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Oral Hypoglycemic Agents and Insulin Analogues Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Insulin Secretagogues Consumption and Growth Rate (2017-2022)

    • Figure Global Alpha-glucosidase Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Global Insulin Sensitizers Consumption and Growth Rate (2017-2022)

    • Figure Global Hospitals Consumption and Growth Rate (2017-2022)

    • Figure Global Drug Store Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Insulin Secretagogues Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Alpha-glucosidase Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Insulin Sensitizers Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Drug Store Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Oral Hypoglycemic Agents and Insulin Analogues Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Oral Hypoglycemic Agents and Insulin Analogues Export by Region (Top 5 Countries) (2017-2028)

    • Table Jiangsu Wanbang (Foundation Year, Company Profile and etc.)

    • Table Jiangsu Wanbang Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Value and Gross Profit (2017-2022)

    • Table Jiangsu Wanbang Oral Hypoglycemic Agents and Insulin Analogues Product and Service

    • Table Novo Nordisk (Foundation Year, Company Profile and etc.)

    • Table Novo Nordisk Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novo Nordisk Oral Hypoglycemic Agents and Insulin Analogues Product and Service

    • Table Tonghua Dongbao (Foundation Year, Company Profile and etc.)

    • Table Tonghua Dongbao Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Value and Gross Profit (2017-2022)

    • Table Tonghua Dongbao Oral Hypoglycemic Agents and Insulin Analogues Product and Service

    • Table Eli Lilly (Foundation Year, Company Profile and etc.)

    • Table Eli Lilly Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Value and Gross Profit (2017-2022)

    • Table Eli Lilly Oral Hypoglycemic Agents and Insulin Analogues Product and Service

    • Table United Laboratory (Foundation Year, Company Profile and etc.)

    • Table United Laboratory Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Value and Gross Profit (2017-2022)

    • Table United Laboratory Oral Hypoglycemic Agents and Insulin Analogues Product and Service

    • Table Ganlee (Foundation Year, Company Profile and etc.)

    • Table Ganlee Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Value and Gross Profit (2017-2022)

    • Table Ganlee Oral Hypoglycemic Agents and Insulin Analogues Product and Service

    • Table Biocon (Foundation Year, Company Profile and etc.)

    • Table Biocon Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Value and Gross Profit (2017-2022)

    • Table Biocon Oral Hypoglycemic Agents and Insulin Analogues Product and Service

    • Table Sanofi-Aventis (Foundation Year, Company Profile and etc.)

    • Table Sanofi-Aventis Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sanofi-Aventis Oral Hypoglycemic Agents and Insulin Analogues Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US